Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systematic Adjunction of Vasopressin in Hyperkinetic Septic Shock
2024-513401-31-00Phase 3Authorised
- Sponsor
- Assistance Publique–Hôpitaux de Marseille
- Start
- Apr 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in septic shock comparing Argipressin (Reverpleg) arm with Placebo (sodium chloride) arm (2 arms). Primary endpoint: SOFA score at 48 hours. Planned start Apr 2025; status: authorised.
02
Drugs
vasopressin
03
Conditions
septic shock
Beyond the preview
Go deeper on 2024-513401-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513401-31-00.